AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024
Apr 22, 2024
32254_dirs_2024-04-22_e1261f1f-28f9-4bd0-9995-97fd229b5a66.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-04-18
Reporting Person: Cormorant Asset Management, LP (N/A)
Reporting Person: Chen Bihua (N/A)
Reporting Person: Cormorant Global Healthcare Master Fund, LP (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-18 | Common Stock | P | 395244 | $17.62 | Acquired | 7288479 | Indirect |
| 2024-04-18 | Common Stock | P | 186521 | $18.9 | Acquired | 7475000 | Indirect |
Footnotes
F1: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F2: Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $17.36 to $18.25 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the "SEC"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.
F3: Represents the weighted average sale right of the shares purchased in a series of open market transactions on the transaction date at prices ranging from $18.43 to $19.06 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.